Globus Medical (GMED) saw its stock decline following a report of setbacks in integrating its recent acquisition and challenges within its surgical robotics division. The company cited lower-than-expected revenue growth in its robotics segment and execution delays in combining operations with its 2024 purchase of a U.S.-based orthopedic tech firm.
- Globus Medical’s robotics segment revenue declined 12% YoY to $14.2M in Q4 2025.
- Integration costs from the LifeSpine acquisition rose to $52M in Q4 2025.
- FDA clearance for new spinal robotics system delayed beyond Q2 2026.
- GMED’s post-acquisition synergy timeline pushed to Q3 2026.
- R&D spending reached $268M in 2025, up 18% from 2024.
- GMED stock dropped 7.3% following the earnings report.
Globus Medical (GMED) posted a 7.3% drop in share price after its quarterly update revealed persistent difficulties in operationalizing its robotics technology and absorbing its 2024 acquisition. The company reported that its robotics segment generated $14.2 million in revenue during Q4 2025, a 12% year-over-year decline, falling short of the $17.8 million projected by analysts. This underperformance was attributed to delays in FDA clearance for its next-generation spinal robotics system, currently in late-stage clinical validation. The acquisition of LifeSpine Technologies (LIFE), completed in November 2024, has also contributed to near-term strain. Integration costs surged to $52 million in Q4 2025, up from $38 million in the prior quarter, primarily driven by workforce restructuring and legacy system migration. Despite a $210 million revenue contribution from the acquired business, post-acquisition synergies remain unachieved, with management stating that full integration is now expected by Q3 2026, pushed back from an initial Q1 2026 timeline. Market reaction was swift, with GMED’s valuation dropping below $24 billion, a 14% correction since its peak in early 2025. Investors are increasingly concerned about the company’s ability to scale innovation amid rising R&D expenditures—$268 million in 2025, up 18% from the previous year—without corresponding revenue gains in high-growth segments. The underperformance has also impacted peer stocks, with Intuitive Surgical (ISRG) seeing a 2.1% dip as analysts reassessed the broader robotics in surgery sector’s near-term viability.